Article

Development and evaluation of a novel multiple-antigen ELISA for serodiagnosis of tuberculosis.

State Key Laboratory of Genetic Engineering, Institute of Genetics, Fudan University, No. 220 Handan Road, 200433 Shanghai, PR China.
Tuberculosis (Edinburgh, Scotland) (Impact Factor: 2.54). 07/2009; 89(4):278-84. DOI: 10.1016/j.tube.2009.05.005
Source: PubMed

ABSTRACT In this study, we describe the development and evaluation of a novel multiple-antigen ELISA for rapid diagnosis and screening of active tuberculosis (TB). The humoral immune responses of 136 active TB patients and 57 healthy subjects against antigens Rv3425, 38kDa and lipoarabinomannan (LAM) from Mycobacterium tuberculosis H37Rv were examined by ELISA. Three essential results were obtained. (i) Rv3425 antigen is a potential candidate for serodiagnosis of active TB. Of 136 active TB patients, Rv3425 antigen provided a sensitivity of 31.6%, lower than that of LAM antigen, but higher than that of 38kDa antigen, with an overall specificity of 100%. (ii) For 62 smear-negative pulmonary TB patients and 15 extra-pulmonary TB patients, the multiple-antigen test provided a sensitivity of 43.5% and 26.7%, respectively, representing an improvement over acid-fast bacilli (AFB) smear-based diagnosis. (iii) Compared with the single-antigen ELISA and the two available commercial kits, the multiple-antigen test offered the highest accuracy (71.0%). In conclusion, the multiple-antigen ELSIA test based on Rv3425, 38kDa, and LAM antigens is a potentially useful tool for the serodiagnosis and screening of active TB. Combinations of Rv3425 with other mycobacterial antigens may also be worthy of further investigation.

0 Bookmarks
 · 
194 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The infection of both captive and free-ranging wildlife species with pathogenic mycobacteria (including Mycobacterium tuberculosis) poses a zoonotic risk and continues to cause challenges for the livestock industry, zoos and governments around the world. Central to the management and control of tuberculosis is timely and accurate diagnosis. In many cases, bacterial culture is insufficiently sensitive and confirmation of TB post-mortem is neither feasible nor desirable. In this context, there is still considerable research interest in, and need for, immunological methods for diagnosis. Reviews on this topic were published in 2005 and 2009, but since then veterinarians and other researchers have continued to evaluate immunodiagnostic approaches to TB. These include serological tests such as lateral-flow devices, and enzyme-linked immunosorbent assay (ELISA) and those based on evaluation of cell-mediated immunity, such as the tuberculin skin test and interferon-gamma release assay (IGRA). Since 2009, the range of publications on this topic has been extended to a number of new species, including South American camelids, black rhinoceros, lions and non-human primates. Therefore, it seemed appropriate to review the literature in the 3 years since 2009 and provide an overview of progress.
    Transboundary and Emerging Diseases 11/2013; 60(s1). · 2.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background/Purpose: Tuberculosis is a crucial health problem. Prevention of the disease requires rapid diagnosis. Rapid liquid culture systems, nucleic acid amplification tests and high-performance liquid chromatography (HPLC) are among the rapid tests used for detecting Mycobacterium species. However, these tests are expensive and require extensive equipment and expertise which is hardly affordable in resource-poor countries. Although direct microscopy is performed routinely as an initial step for detection of the bacteria, it is not sufficiently sensitive. As a result, we thought of establishing a low-cost immunological test that can potentially replace direct microscopy with higher sensitivity and specificity. Method: The assay is based on pre-incubation of biotinylated rabbit antibody against Antigen 60 with a solution containing Bacillus Calmette-Guerin (BCG) or Mycobacterium tuberculosis (MTB) followed by incubation with streptavidin-alkaline phosphatase conjugate. The test is devised in ELISA and non-ELISA formats so that it may not require extensive facilities and expertise. Results: The ELISA format has shown a 100-fold improvement in lower detection limit of BCG comparing to direct microscopy. In non-ELISA formats, this amount was 2 and 16-fold improvement for cartridge assay and microfuge tube assay, respectively. Conclusion: In conclusion, we successfully detected BCG and Mycobacterium tuberculosis in solution using the new immunological method. Our results are very promising and the new immunological method could potentially replace direct microscopy with higher sensitivity and specificity.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 04/2014; · 1.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antigens encoded in the region of difference (RD) of Mycobacterium tuberculosis constitute a potential source of specific immunodiagnostic antigens for distinguishing tuberculosis (TB) infection from BCG vaccination. We evaluated the diagnostic potential of specific T-cell epitopes selected from two recently identified immunodominant antigens Rv1985c and Rv3425 from RD2 and RD11 based on epitope mapping in TB patients and BCG-vaccinated healthy individuals. Using a whole blood IFN-γ release assay, a wide array of epitopes was recognized on both Rv1985c and Rv3425 in TB patients. Those epitopes that could specifically discriminate TB infection from BCG-vaccination were carefully selected, and the most promising peptide pools from Rv1985c showed a sensitivity of 53.9% and specificity of 95.5%. When the novel specific peptides from Rv1985c joined the diagnostic antigens in the QuantiFERON®-TB Gold In-Tube (QFT-IT) assay, the sensitivity was increased from 86.4% to 96.2% with no drop in specificity. These results indicated that the selected peptide pools from Rv1985c and Rv3425 would have the potential to diagnose TB infection for routine use in clinical laboratories.
    Clinical and vaccine Immunology: CVI 11/2012; · 2.60 Impact Factor

Full-text

View
130 Downloads
Available from
May 21, 2014